Flavokawain B is primarily studied for its potential therapeutic applications, particularly in cancer research. It has shown promise in inducing apoptosis, or programmed cell death, in various cancer cell lines, including prostate, breast, and bladder cancers. This compound is believed to work by targeting specific cellular pathways, such as the inhibition of NF-κB signaling, which plays a role in cancer cell survival and proliferation. Additionally, Flavokawain B has been investigated for its anti-inflammatory and antioxidant properties, making it a candidate for managing chronic inflammatory conditions and oxidative stress-related diseases. Its ability to modulate key molecular targets also suggests potential use in developing novel chemotherapeutic agents or adjunct therapies in oncology. Research is ongoing to further explore its efficacy and safety in preclinical and clinical settings.